BACKGROUND AND OBJECTIVE Recently, the incidence of non-Hodgkin's lymphoma (NHL) is increasing, in which most are aggressive. It is limited for promoting the efficacy of conventional chemotherapy on NHL. In this study, mouse models of B-cell NHL were established for determining the efficacy and mechanisms of novel therapies. METHODS Diffuse large B-cell lymphoma SU-DHL-4 cells and Burkitt's l...

Cells from an established line of Burkitt's lymphoma (Daudi) and a mouse myeloma (P(3)K) were pulse-labeled in vitro with (3)H-leucine, and immunoglobulin was immunologically precipitated from cell lysates and secretions. In contrast to P(3)K cells, Daudi cells synthesize a small amount of Ig which is not secreted. Subcellular fractionation experiments indicated that Ig of Daudi cells is synthe...

The Daudi line of human lymphoblastoid cells requires insulin and transferrin for growth in serumfree medium and is highly sensitive to the inhibitory effect of human leukocyte interferon (IFN-a) on cell proliferation. A variant subline of Daudi cells, which is resistant to the antiproliferative action of IFN-a, also has been grown in serum-free medium containing insulin and transferrin. The pr...

LL2, an anti-CD22 monoclonal antibody against B-cell lymphoma, was covalently linked to the amphibian ribonuclease, onconase, a member of the pancreatic RNase A superfamily. LL2 increased in vitro potency (10 000-fold) and specificity against human Daudi Burkitt lymphoma cells while decreasing systemic toxicity of onconase. Monensin further increased potency of LL2-onconase on Daudi cells (IC(5...

After a 3-day exposure to 0.1 microM 1-beta-D-arabinofuranosylcytosine (ara-C) in culture, growth was inhibited to 5.6% in MOLT-4F, 25% in Raji, and 91% in Daudi cells compared with control. Growth inhibition was more profound when exposure time was extended up to 7 days. Inhibition of DNA synthesis varied with sensitivity to ara-C. Plateau levels of intracellular 1-beta-D-arabinofuranosylcytos...

The antitumor activities of immunotoxins (ITs) constructed with deglycosylated ricin A chain (dgA) and either anti-CD19 (HD37) or anti-CD22 (RFB4) monoclonal antibodies were compared in SCID mice with disseminated human Daudi lymphoma (SCID/Daudi). As reported previously, after intravenous injection with Daudi cells, SCID mice develop disseminated lymphoma, which infiltrates the vertebral colum...

Treatment of Daudi cells with successively increasing concentrations of interferon-alpha resulted in the selection of a cell population which multiplied in the continued presence of 10(4) units/ml of interferon-alpha. A number of clones of interferon-resistant Daudi cells were isolated from this population. Two clones, DIF2 and DIF3, were found to exhibit moderate and pronounced resistance, res...

Severe combined immunodeficient (SCID) mice injected intravenously with a human Burkitt’s lymphoma cell line (Daudi) develop disseminated lymphoma (SCID/Daudi), which is fatal in 100% of the mice. Early treatment of these mice with either an immunotoxin (IT) cocktail (consisting of anti-CD19-ricin A chain plus anti-CD=-ricin A chain) or chemotherapy significantly prolonged survival but w...

Severe combined immunodeficient (SCID) mice injected intravenously with a human Burkitt’s lymphoma cell line (Daudi) develop disseminated lymphoma (SCID/Daudi), which is fatal in 100% of the mice. Early treatment of these mice with either an immunotoxin (IT) cocktail (consisting of anti-CD19-ricin A chain plus anti-CD=-ricin A chain) or chemotherapy significantly prolonged survival but w...